Pharmacokinetics (PK) Screen

Our DMPK experts help steer your project to success with a clear insight into the pharmacokinetics of your therapeutic. The team develop impactful in vivo PK studies before generating and interpreting data that helps you make informed decisions about the next stage of your project.

• All you provide is 1mg of your compound and we do the rest. We provide blank matrices which are ethical, sustainable and enable us to fix your study costs
• A PK Screen provides you with a comprehensive experience of our service, whatever the scope of your future study needs, and allows the magnitude of method development to be assessed if required
• We provide you with a comprehensive and concise PK screening summary document containing analytical summary and comments, methodology, raw data, working solution scheme and representative chromatography.

PK screen case study (UK Biotech DMPK group):

‍Our client requested to screen a compound, in 2 matrices, with a view to having us perform sample analysis work for both if the desired LLOQ could be reached. They had struggled to analyze the samples accurately due to interference/contamination from analogous compounds with similar daughter ions. A screen was performed, uncovering that there was an endogenous response in one matrix, but the desired LLOQ was reached in the other comfortably. Following the initial screen with one matrix the client expanded their project to include further matrices.

‍
PK screening service

‍Using 1 mg or less of material, we can screen your compound(s) to ensure that our existing discovery methodologies are compatible for your requirements. We will optimize MS and LC parameters for your compound under generic conditions, and extract a calibration curve, quality control samples in triplicate, and double blanks in triplicate, in your matrix or matrices of choice, to identify any indicators of issues such as ion suppression, protein binding and non-specific binding, early in the process. 

‍
This cost-effective option provides reassurance that sample analyses will proceed smoothly once your study commences, or highlights the need for further method development, prior to sample analysis issues. Furthermore, screening prevents animals from being prematurely dosed, if compounds require significant method development, contributing to our ethical approach to bioanalysis. 

‍
Our expert team have pre-determined target criteria, designed to maximize the potential of your study, but as always, we welcome discussion with you to identify your exact requirements. Results of the PK screening option are collated and provided in a clear and concise report format, provided to you via your data transfer route of choice. This leaves you with the right information at the right time to progress to the next key milestone.
‍

What does a PK Screen consist of:

• Compound optimization
• Chromatography assessment on generic column with generic gradient
• Extraction in desired matrix/matrices (control tissue to be supplied if not in stock):
  • Single calibration curve (0.5-2000ng/mL)
  • Triplicate QC sets (6 QCs, 1-1000ng/mL)
  • Triplicate double blanks
• Processing of results using Targetlynx
• PK Screening summary via excel with recommendations and interpretation
• Just one day to provide you with a preliminary assessment

What is contained in your report:

• Clear and concise PK Screening summary document provided with:
• Analytical summary and comments
• Methodology
• Raw data
• Working solution scheme
• Representative chromatography
  
  

Find out how we can help you rapidly evaluate the PK of your therapeutic and have a confidential discussion with our experts about your project needs.